Neogen Q1 Earnings Miss Estimates, Margins Crash

Zacks10-15

Neogen Corporation NEOG reported first-quarter fiscal 2025 adjusted earnings per share (EPS) of 7 cents, down 36.4% from the prior-year quarter's registered numbers. The bottom line missed the Zacks ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475877946?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/46gFT4Y7HZuuo2Xj6ImXmw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/35df2d293bff824e6b9f2134b8f740a3","is_english":true,"pubTime":"2024-10-15 20:55","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2475877946","market":"us","top_or_hot":-1,"title":"Neogen Q1 Earnings Miss Estimates, Margins Crash","media":"Zacks","content":"<div>\n<p>Neogen Corporation NEOG reported first-quarter fiscal 2025 adjusted earnings per share (EPS) of 7 cents, down 36.4% from the prior-year quarter's registered numbers. The bottom line missed the Zacks ...</p>\n\n<a href=\"https://finance.yahoo.com/news/neogen-q1-earnings-miss-estimates-125500864.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neogen Q1 Earnings Miss Estimates, Margins Crash</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeogen Q1 Earnings Miss Estimates, Margins Crash\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-15 20:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/neogen-q1-earnings-miss-estimates-125500864.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neogen Corporation NEOG reported first-quarter fiscal 2025 adjusted earnings per share (EPS) of 7 cents, down 36.4% from the prior-year quarter's registered numbers. The bottom line missed the Zacks ...</p>\n\n<a href=\"https://finance.yahoo.com/news/neogen-q1-earnings-miss-estimates-125500864.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEOG","symbol_name":"纽尔真检测","start_time":0,"source_url":"https://finance.yahoo.com/news/neogen-q1-earnings-miss-estimates-125500864.html","article_id":"2475877946","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/46gFT4Y7HZuuo2Xj6ImXmw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/35df2d293bff824e6b9f2134b8f740a3"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475877946","pubTimestamp":1728996900,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Neogen CorporationNEOG reported first-quarter fiscal 2025 adjusted earnings per share  of 7 cents, down 36.4% from the prior-year quarter's registered numbers. The bottom line missed the Zacks Consensus Estimate by 30%.Revenues fell 5.2% on a year-over-year basis to $217 million. Core revenues declined 1.4%. Acquisitions and discontinued product lines did not impact core growth, while foreign currency had a negative impact of 3.9%. However, the metric surpassed the Zacks Consensus Estimate by 0.4%.Stay up-to-date with all quarterly releases:See Zacks Earnings Calendar.Revenues fromAnimal Safetytotaled $57.6 million, down 8.1% year over year. Our model’s projection was $64 million. This consisted of a 7.8% core revenue decline and a 0.3% headwind from discontinued products. On a global basis, the company’s Genomics business experienced a core revenue decline in the mid-single-digit range.Neogen exited thefiscal first quarter on a mixed note, wherein earnings missed","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NEOG":"纽尔真检测"},"translate_title":"Neogen第一季度盈利未达预期，利润率暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEOG":0.9},"content_text":"Neogen Corporation NEOG reported first-quarter fiscal 2025 adjusted earnings per share (EPS) of 7 cents, down 36.4% from the prior-year quarter's registered numbers. The bottom line missed the Zacks Consensus Estimate by 30%.\nRevenues fell 5.2% on a year-over-year basis to $217 million. Core revenues declined 1.4%. Acquisitions and discontinued product lines did not impact core growth, while foreign currency had a negative impact of 3.9%. However, the metric surpassed the Zacks Consensus Estimate by 0.4%.\nStay up-to-date with all quarterly releases:See Zacks Earnings Calendar.\nNeogen’s Segments in Detail\nThe company's Food Safety segment registered revenues of $159.3 million, marking a 4.2% decrease year over year. Our model projected the segment’s revenues to be $152.3 million for the fiscal first quarter. This consisted of 1.1% core growth, a 0.1% contribution from acquisitions and discontinued product lines and a negative foreign currency impact of 5.4%. The core revenue growth was led by solid performance in biosecurity and indicator testing, culture media & other product categories, including Petrifilm.\nRevenues from Animal Safety totaled $57.6 million, down 8.1% year over year. Our model’s projection was $64 million. This consisted of a 7.8% core revenue decline and a 0.3% headwind from discontinued products. On a global basis, the company’s Genomics business experienced a core revenue decline in the mid-single-digit range.\nNeogen’s Margin Details\nThe fiscal first-quarter gross profit declined 10.1% year over year to $104.9 million. The gross margin contracted 263 basis points (bps) to 48.4% despite a 0.2% decrease in the cost of revenues.\nSales and marketing expenses amounted to $45.8 million, almost flat year over year, whereas administrative expenses increased 14.5% from the prior-year quarter to $51.7 million. R&D expenses totaled $5.2 million, down 22.7% year over year. Operating costs totaled $102.7 million, up 5.2% from that reported a year ago. The operating margin fell 732 bps in the quarter under review.\nNeogen’s Cash Position\nNeogen exited the first quarter with cash and cash equivalents of $120.5 million compared with $170.6 million at the end of fiscal 2024. The company’s non-current liabilities included a total outstanding debt of $900 million and committed borrowing headroom of $150 million.\nNeogen Corporation Price, Consensus and EPS Surprise\n\n\nNeogen Corporation price-consensus-eps-surprise-chart | Neogen Corporation Quote\n\nNeogen’s Full-Year Guidance\nNeogen maintained its previously stated financial outlook for fiscal 2025.\nThe company anticipates full-year revenues to be between $925 million and $955 million. The Zacks Consensus Estimate is currently pegged at $983.2 million.\nCapital expenditures are likely to be approximately $85 million, including almost $55 million related to the integration of the former 3M Food Safety Division. \nOur Take\nNeogen exited the fiscal first quarter on a mixed note, wherein earnings missed the Zacks Consensus Estimate but revenues beat the same. The Animal Safety segment posted lower quarterly sales due to lower sales in animal care & other and biosecurity product categories.\nWithin Food Safety, core growth was led by Indicator Testing, Culture Media and other product categories, which benefited from strong growth in the Petrifilm product line and Food Quality, Nutritional Analysis and Culture Media. Despite the successful reallocation of the 3M sample collection product line, the company fell short of keeping up with end-user demand, which weighed on the sample collection sales in the quarter.\nAdditionally, the contraction of both margins in the quarter is discouraging. Foreign currency turned out to be a major headwind.\nNEOG’s Zacks Rank and Key Picks\nNeogen currently carries a Zacks Rank #4 (Sell).\nSome better-ranked stocks from the broader medical space are Addus HomeCare ADUS, AdaptHealth Corp. AHCO and Abbott Laboratories, Inc. ABT.\nAddus HomeCare sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here\nThe company reported a second-quarter adjusted EPS of $1.35, which surpassed the Zacks Consensus Estimate by 12.5%. Revenues of $286.9 million exceeded the Zacks Consensus Estimate by 1.1%. ADUS beat on earnings in each of the trailing four quarters, the average surprise being 11.45%.\nAdaptHealth, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2024 EPS of $2.11, which surpassed the Zacks Consensus Estimate by 10.5%. Revenues of $806 million topped the consensus estimate by 0.4%. The company’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 40.97%.\nAbbott, carrying a Zacks Rank #2 at present, reported second-quarter 2024 EPS of $1.14, which surpassed the Zacks Consensus Estimate by 3.6%. Revenues of $10.38 billion topped the Zacks Consensus Estimate by 0.3%. The company beat on earnings in each of the trailing four quarters, the average surprise being 2.34%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAbbott Laboratories (ABT) : Free Stock Analysis Report\nNeogen Corporation (NEOG) : Free Stock Analysis Report\nAddus HomeCare Corporation (ADUS) : Free Stock Analysis Report\nAdaptHealth Corp. (AHCO) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475877946"}